A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination with Ipilimumab Nivolumab and Relatlimab in Patients with Unresectable Stage III or Stage IV Melanoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Melanoma
    Unresectable Melanoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. All patients must be either Stage IIIb/c/d or Stage IV melanoma according to the American Joint Committee on Cancer (AJCC) (8th edition) and have histologically-confirmed melanoma that is felt to be surgically unresectable or metastatic
    2. Prior treated CNS metastases must be without MRI evidence of recurrence for at least 4 weeks after treatment
    3. Prior surgery that required general anesthesia must be completed at least 2 weeks before study drug administration

You may not be eligible for this study if the following are true:

    1. Active or history of steroid-requiring non-infectious pneumonitis
    2. Previously discontinued adjuvant immunotherapy due to an immune-mediated adverse reaction of grade 4
    3. Untreated brain metastases, carcinomatosis meningitis or a history of current ocular/uveal melanoma



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.